Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen P Salloway

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Neuroimage|July 12, 2008
Quantitative tractography metrics of white matter integrity in diffusion-tensor MRIStephen Correia, Stephanie Y Lee, Thom Voorn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 2, 2024
Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosisMatthew D Howe, Megan R Caruso, Masood Manoochehri, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 21, 2006
Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorderBenjamin D Greenberg, Donald A Malone, Gerhard M Friehs, et al.
Alzheimer'S Research & Therapy|March 27, 2020
Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay intervalJessica Alber, Paul Maruff, Cláudia Y Santos, et al.
Journal of Alzheimer'S Disease : JAD|June 20, 2018
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension StudyStephen P Salloway, Reisa Sperling, Nick C Fox, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 12, 2020
Advancing combination therapy for Alzheimer's diseaseStephen P Salloway, Jeff Sevingy, Kumar Budur, et al.
Biological Psychiatry|January 24, 2018
Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive DisorderSteven A Rasmussen, Georg Noren, Benjamin D Greenberg, et al.
Research Square|June 10, 2024
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's diseaseMatthew D Howe, Karysa J Britton, Hannah E Joyce, et al.
Alzheimer'S Research & Therapy|July 6, 2024
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's diseaseMatthew D Howe, Karysa J Britton, Hannah E Joyce, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Neuroimage|July 12, 2008
Quantitative tractography metrics of white matter integrity in diffusion-tensor MRIStephen Correia, Stephanie Y Lee, Thom Voorn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 2, 2024
Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosisMatthew D Howe, Megan R Caruso, Masood Manoochehri, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 21, 2006
Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorderBenjamin D Greenberg, Donald A Malone, Gerhard M Friehs, et al.
Alzheimer'S Research & Therapy|March 27, 2020
Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay intervalJessica Alber, Paul Maruff, Cláudia Y Santos, et al.
Journal of Alzheimer'S Disease : JAD|June 20, 2018
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension StudyStephen P Salloway, Reisa Sperling, Nick C Fox, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 12, 2020
Advancing combination therapy for Alzheimer's diseaseStephen P Salloway, Jeff Sevingy, Kumar Budur, et al.
Biological Psychiatry|January 24, 2018
Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive DisorderSteven A Rasmussen, Georg Noren, Benjamin D Greenberg, et al.
Research Square|June 10, 2024
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's diseaseMatthew D Howe, Karysa J Britton, Hannah E Joyce, et al.
Alzheimer'S Research & Therapy|July 6, 2024
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's diseaseMatthew D Howe, Karysa J Britton, Hannah E Joyce, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
Pageof 5